Dr Grajales-Cruz on Real-World Teclistamab Data in BCMA-Pretreated Multiple Myeloma
Ariel Grajales-Cruz, MD, discusses the rationale for a real-world study of teclistamab in patients with myeloma who had received BCMA-directed therapy.
Ariel Grajales Cruz Department Of Malignant Hematology Moffitt Cancer Center University Of South Florida Malignant Hematology Multiple Myeloma Section
Source: onclive.com